Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment

被引：0
|
作者：
Groop, P. -H. [1 ,2 ]
Laakso, M. [3 ,4 ]
Rosenstock, J. [5 ]
Hehnke, U. [6 ]
Tamminen, I. [7 ]
Patel, S. [8 ]
von Eynatten, M. [6 ]
Woerle, H. -J. [6 ]
机构：
[1] Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki, Finland
[2] Biomed Helsinki, Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[3] Univ Eastern Finland, Dept Med, Kuopio, Finland
[4] Kuopio Univ Hosp, SF-70210 Kuopio, Finland
[5] Med City, Dallas Diabet & Endocrine Ctr, Dallas, TX USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[7] Boehringer Ingelheim GmbH & Co KG, Helsinki, Finland
[8] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
914
引用
收藏
页码：S364 / S365
页数：2
相关论文
共 50 条
  • [41] Novartis drug Vildagliptin shown to be well-tolerated and effective in patients with type 2 diabetes and moderate or severe renal impairment
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2011, 13 (11): : 1060 - 1060
  • [42] THE IMPACT OF SEVERE HYPOGLYCEMIA ON RENAL IMPAIRMENT IN TYPE 2 DIABETES
    Lee, Y. -L.
    Chen, B. K.
    Lin, K. -D.
    Su, R. -W.
    Lee, M. -Y.
    Shin, S. -J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S106 - S107
  • [43] The impact of severe hypoglycemia on renal impairment in type 2 diabetes
    Lee, Yu-Li
    Chen, Brian K.
    Lin, Kun-Der
    Su, Rong-Wei
    Lee, Mei-Yueh
    Hsiao, Pi-Jung
    Shin, Shyi-Jang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 108 (03) : 448 - 455
  • [44] Baseline characteristics of participants enrolled in the cardiovascular outcome study of linagliptin versus glimepiride in early type 2 diabetes (CAROLINA)
    Marx, N.
    Rosenstock, J.
    Kahn, S. E.
    Zinman, B.
    Kastelein, J. J.
    Lachin, J.
    Espeland, M. A.
    Bluhmki, E.
    Mattheus, M.
    Patel, S.
    Johansen, O.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S36 - S37
  • [45] ANTIDIABETIC MEDICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND SEVERE RENAL IMPAIRMENT: AN UPDATE
    Aperis, Georgios
    JOURNAL OF RENAL CARE, 2012, 38 (03) : 170 - 171
  • [46] Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
    Lukashevich, Valentina
    Schweizer, Anja
    Foley, James E.
    Dickinson, Sheila
    Groop, Per-Henrik
    Kothny, Wolfgang
    VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 21 - 28
  • [47] Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study
    Han, Sang Youb
    Yoon, Sun Ae
    Han, Byoung Geun
    Kim, Sung Gyun
    Jo, Young-Il
    Jeong, Kyung Hwan
    Oh, Kook-Hwan
    Park, Hyeong Cheon
    Park, Sun-Hee
    Kang, Shin-Wook
    Na, Ki-Ryang
    Kang, Sun Woo
    Kim, Nam-Ho
    Jang, Younghwan
    Kim, Bogyeong
    Shin, Seonghye
    Cha, Dae Ryong
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 292 - 300
  • [48] Rosiglitazone added to a sulphonylurea in patients with type 2 diabetes and mild-to-moderate renal impairment
    Agrawal, A
    Jones, NP
    Sautter, M
    DIABETOLOGIA, 2000, 43 : A191 - A191
  • [49] Rationale and design of the CAROLINA®-cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
    Biessels, Geert Jan
    Janssen, Jolien
    van den Berg, Esther
    Zinman, Bernard
    Espeland, Mark A.
    Mattheus, Michaela
    Johansen, Odd Erik
    BMC NEUROLOGY, 2018, 18
  • [50] Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment ( LIRA-RENAL): A Randomized Clinical Trial
    Davies, Melanie J.
    Bain, Stephen C.
    Atkin, Stephen L.
    Rossing, Peter
    Scott, David
    Shamkhalova, Minara S.
    Bosch-Traberg, Heidrun
    Syren, Annika
    Umpierrez, Guillermo E.
    DIABETES CARE, 2016, 39 (02) : 222 - 230
12345